Triggers of Hospitalization for Venous Thromboembolism

Background— The rate of hospitalization for venous thromboembolism (VTE) is increasing in the United States. Although predictors of hospital-acquired VTE are well-known, triggers of VTE before hospitalization are not as clearly defined. The objective of this study was to evaluate triggers of hospitalization for VTE. Methods and Results— A case-crossover study was conducted. Subjects were participants in the Health and Retirement Study, a nationally representative sample of older Americans. Data were linked to Medicare files for hospital and nursing home stays, emergency department visits, outpatient visits including physician visits, and home health visits from years 1991 to 2007 (n=16 781). The outcome was hospitalization for venous thromboembolism (n=399). Exposures during the 90-day period before hospitalization for VTE were compared with exposures occurring in 4 comparison periods. Infection was the most common trigger of hospitalization for VTE, occurring in 52.4% of the risk periods before hospitalization. The adjusted incidence rate ratios (IRRs; 95% confidence interval) were 2.90 (2.13, 3.94) for all infection, 2.63 (1.90, 3.63) for infection without a previous hospital or skilled nursing facility stay, and 6.92 (4.46, 10.72) for infection with a previous hospital or skilled nursing facility stay. Erythropoiesis-stimulating agents and blood transfusion were also associated with VTE hospitalization (IRR=9.33, 95% confidence interval: 1.19, 73.42; IRR=2.57, 95% confidence interval: 1.17, 5.64; respectively). Other predictors included major surgeries, fractures (IRR=2.81), immobility (IRR=4.23), and chemotherapy (IRR=5.70). These predictors, combined, accounted for a large proportion (69.7%) of exposures before VTE hospitalization as opposed to 35.3% in the comparison periods. Conclusions— Risk prediction algorithms for VTE should be reevaluated to include infection, erythropoiesis-stimulating agents, and blood transfusion.

[1]  W. Baine,et al.  The Agency for Healthcare Research and Quality , 2006, Italian Journal of Public Health.

[2]  D. Davenport,et al.  Association of blood transfusion and venous thromboembolism after colorectal cancer resection. , 2012, Thrombosis research.

[3]  L. Smeeth,et al.  Acute infections and venous thromboembolism , 2011, Journal of internal medicine.

[4]  J. Carson,et al.  Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. , 2012, The Cochrane database of systematic reviews.

[5]  T. McMahon,et al.  Impaired adenosine-5′-triphosphate release from red blood cells promotes their adhesion to endothelial cells: A mechanism of hypoxemia after transfusion* , 2011, Critical care medicine.

[6]  Jason D. Wright,et al.  Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Turpie,et al.  Predictive and associative models to identify hospitalized medical patients at risk for VTE. , 2011, Chest.

[8]  Carol Coupland,et al.  Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study , 2011, BMJ : British Medical Journal.

[9]  Ruihua Yin,et al.  H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. , 2011, American journal of preventive medicine.

[10]  M. Mittleman,et al.  Recent Advances in Preventive Cardiology and Lifestyle Medicine Physical, Psychological and Chemical Triggers of Acute Cardiovascular Events Preventive Strategies , 2011 .

[11]  T. van der Poll,et al.  The effect of inflammation on coagulation and vice versa , 2011, Current opinion in infectious diseases.

[12]  T. Meade,et al.  Recent respiratory infection and risk of venous thromboembolism: case–control study through a general practice database , 2011, International journal of epidemiology.

[13]  A. Neugut,et al.  Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Hippisley-Cox,et al.  Antipsychotic drugs and risk of venous thromboembolism: nested case-control study , 2010, BMJ : British Medical Journal.

[15]  Banafsheh Sadeghi,et al.  Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. , 2010, Thrombosis research.

[16]  Georg Heinze,et al.  Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism: The Vienna Prediction Model , 2010, Circulation.

[17]  Janet S. Lee,et al.  Bad Blood: The risks of red cell storage , 2010, Nature Medicine.

[18]  E. Unger,et al.  Erythropoiesis-stimulating agents--time for a reevaluation. , 2010, The New England journal of medicine.

[19]  A. Khorana,et al.  Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. , 2008, Archives of internal medicine.

[20]  Liam Smeeth,et al.  Exposure to antipsychotics and risk of stroke: self controlled case series study , 2008, BMJ : British Medical Journal.

[21]  D. Dorr,et al.  Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. , 2008, JAMA.

[22]  Patrick Musonda,et al.  Tutorial in biostatistics: the self‐controlled case series method , 2006, Statistics in medicine.

[23]  R. Hubbard,et al.  Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting , 2006, The Lancet.

[24]  Pieter W Kamphuisen,et al.  Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. , 2006, JAMA.

[25]  S. Doucette,et al.  Does this patient have deep vein thrombosis? , 1998, JAMA.

[26]  D. Wagner,et al.  New links between inflammation and thrombosis. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[27]  A. Turpie,et al.  Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. , 2004, Archives of internal medicine.

[28]  C. Esmon The impact of the inflammatory response on coagulation. , 2004, Thrombosis research.

[29]  N. Roubinian,et al.  Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. , 2016, The Cochrane database of systematic reviews.

[30]  J. Johannigman,et al.  The risk assessment profile score identifies trauma patients at risk for deep vein thrombosis. , 2000, Surgery.

[31]  M Maclure,et al.  Should we use a case-crossover design? , 2000, Annual review of public health.

[32]  M Gent,et al.  Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer , 2000, Thrombosis and Haemostasis.

[33]  R. Suzman,et al.  An Overview of the Health and Retirement Study , 1995 .

[34]  M. Maclure The case-crossover design: a method for studying transient effects on the risk of acute events. , 1991, American journal of epidemiology.